Abstrato

A Systemic Review of healthcare, hematologic malignancies.

Graeme Fraser

The use of genetic studies for diagnosis, categorization, prognostication, and therapeutic decisionmaking has historically been pioneered by hematologic malignancies. With expanded genomic analysis of cancer and advancements in molecular diagnostic technology, genetic characterization has become increasingly important in the clinical evaluation of almost all types of hematologic malignancies. In this article, we discuss the role that genetic analysis plays in the diagnosis and/ or treatment of acute leukemias, chronic myeloid neoplasms, B- and T-NK-cell lymphomas, and multiple myeloma. We pay special attention to the genetic changes required to make diagnoses and/or choose appropriate clinical treatment.